(DMP) Dermapharm Holding SE - Ratings and Ratios

Dermapharm Holding SE is a leading European player in the pharmaceutical industry, operating through three distinct segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. The company has established a strong presence in Germany, France, Spain, Austria, Switzerland, and beyond, offering a diverse portfolio of off-patent branded pharmaceutical products, including branded generics, OTC products, and herbal extracts. Additionally, Dermapharm provides a range of healthcare products, such as vitamins, minerals, and food supplements, as well as products for specific medical needs, including dermatology, allergology, and cardiovascular support.

The companys product portfolio is marketed under various brand names, including Dekristol, Keltican, Tromcardin, and Herpotherm, with a significant presence in the European market. Dermapharms business model is built around the import and distribution of pharmaceutical products, including parallel-imported originator pharmaceuticals under the axicorp brand. With a history dating back to 1991, the company has established itself as a reputable player in the industry, headquartered in Grünwald, Germany, and is a subsidiary of Themis Beteiligungs-AG.

Analyzing the , we observe that the stock has recently traded at €35.65, slightly above its 20-day Simple Moving Average (SMA) of €35.48, indicating a potential bullish trend. However, the stock remains below its 50-day SMA (€36.78) and 200-day SMA (€36.54), suggesting a longer-term bearish trend. The Average True Range (ATR) of €0.95 (2.66%) indicates moderate volatility. Considering the , Dermapharms Market Cap stands at €2034.81M, with a Price-to-Earnings (P/E) ratio of 18.72 and a Forward P/E of 14.62, indicating a relatively attractive valuation. The Return on Equity (RoE) of 17.42% suggests a strong profitability.

Based on the analysis of and , our forecast suggests that Dermapharm Holding SE is poised for a potential rebound in the short term, driven by its strong product portfolio and improving profitability. We expect the stock to trade towards €38.50 in the next 6-12 months, representing a 8% upside from current levels. However, investors should be cautious of the longer-term bearish trend and monitor the stocks performance relative to its SMAs. A break above the 50-day SMA (€36.78) could be a positive catalyst, while a decline below the 52-week low (€30.15) could indicate a more significant downturn.